Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114624 | 0.87 | CNR1 (0.48) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL17866269 | 0.86 | KCNH2 (0.46) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2112441 | 0.85 | CNR1 (0.52) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2112015 | 0.84 | CNR1 (0.49) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2114487 | 0.84 | KCNH2 (0.53) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2113379 | 0.83 | KDM4E (0.55) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2113414 | 0.83 | CNR1 (0.54) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2114614 | 0.83 | CNR1 (0.49) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2114838 | 0.82 | CNR1 (0.55) | CNR1KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL2115180 | 0.82 | CNR1 (0.51) | CNR1KCNH2SCN5ASCN2ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | APOB, CETP, NPC1L1 | CNR1 68/4885KCNH2 839/4885SCN5A 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.